Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central nervous system, conolidine modulates alternate molecular targets. A Science Advancements examine uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, whi… Read More